{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T00:55:29Z","timestamp":1794099329327,"version":"4.8.0"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T00:00:00Z","timestamp":1731888000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Foundation","doi-asserted-by":"publisher","award":["NNF19OC0054908"],"award-info":[{"award-number":["NNF19OC0054908"]}],"id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Foundation","doi-asserted-by":"publisher","award":["NNF22SA0079901"],"award-info":[{"award-number":["NNF22SA0079901"]}],"id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015223","name":"Danish Diabetes and Endocrine Academy","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015223","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background and Aims<\/jats:title>\n                  <jats:p>The bleeding risk of using non-steroidal anti-inflammatory drugs (NSAIDs) in patients treated with oral anticoagulants for venous thromboembolism (VTE) remains unclear.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A nationwide cohort study of 51 794 VTE patients initiating oral anticoagulants between 1 January 2012 and 31 December 2022 was conducted. Time-dependent multivariate cause-specific Cox regression was used to compute adjusted hazard ratios between NSAID use and hospital-diagnosed bleeding episodes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Event rates for any bleeding per 100 person-years were 3.5 [95% confidence interval (CI), 3.4\u20133.7] during periods without NSAID use and 6.3 (95% CI, 5.1\u20137.9) during periods with NSAID use (number needed to harm = 36 patients treated for 1 year). Compared with non-use, the adjusted hazard ratios for any bleeding associated with NSAID use were 2.09 (95% CI, 1.67\u20132.62) overall, 1.79 (95% CI, 1.36\u20132.36) for ibuprofen, 3.30 (95% CI, 1.82\u20135.97) for diclofenac, and 4.10 (95% CI, 2.13\u20137.91) for naproxen. Compared with non-use, the adjusted hazard ratios associated with NSAID use were 2.24 (95% CI, 1.61\u20133.11) for gastrointestinal bleeding, 3.22 (95% CI, 1.69\u20136.14) for intracranial bleeding, 1.36 (95% CI, .67\u20132.77) for thoracic and respiratory tract bleeding, 1.57 (95% CI, .98\u20132.51) for urinary tract bleeding, and 2.99 (95% CI, 1.45\u20136.18) for anaemia caused by bleeding. Results were consistent for anticoagulant and VTE subtypes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Patients treated with oral anticoagulants for VTE had a more than two-fold increased bleeding rate when using NSAIDs. This increased bleeding rate was not restricted to the gastrointestinal tract.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/eurheartj\/ehae736","type":"journal-article","created":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T04:24:51Z","timestamp":1731903891000},"page":"58-68","source":"Crossref","is-referenced-by-count":23,"title":["Bleeding risk using non-steroidal anti-inflammatory drugs with anticoagulants after venous thromboembolism: a nationwide Danish study"],"prefix":"10.1093","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0267-0561","authenticated-orcid":false,"given":"S\u00f8ren Riis","family":"Petersen","sequence":"first","affiliation":[{"name":"Department of Clinical Epidemiology, Aarhus University Hospital , Olof Palmes All\u00e9 43\u201345, 8200 Aarhus N ,","place":["Denmark"]},{"name":"Department of Clinical Medicine, Faculty of Health, Aarhus University , Palle Juul-Jensens Boulevard 82, 8200 Aarhus N ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8626-2372","authenticated-orcid":false,"given":"Kasper","family":"Bonnesen","sequence":"additional","affiliation":[{"name":"Department of Clinical Epidemiology, Aarhus University Hospital , Olof Palmes All\u00e9 43\u201345, 8200 Aarhus N ,","place":["Denmark"]},{"name":"Department of Clinical Medicine, Faculty of Health, Aarhus University , Palle Juul-Jensens Boulevard 82, 8200 Aarhus N ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1466-0865","authenticated-orcid":false,"given":"Erik Lerkevang","family":"Grove","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, Faculty of Health, Aarhus University , Palle Juul-Jensens Boulevard 82, 8200 Aarhus N ,","place":["Denmark"]},{"name":"Department of Cardiology, Aarhus University Hospital , Aarhus ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9341-3888","authenticated-orcid":false,"given":"Lars","family":"Pedersen","sequence":"additional","affiliation":[{"name":"Department of Clinical Epidemiology, Aarhus University Hospital , Olof Palmes All\u00e9 43\u201345, 8200 Aarhus N ,","place":["Denmark"]},{"name":"Department of Clinical Medicine, Faculty of Health, Aarhus University , Palle Juul-Jensens Boulevard 82, 8200 Aarhus N ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4935-4059","authenticated-orcid":false,"given":"Morten","family":"Schmidt","sequence":"additional","affiliation":[{"name":"Department of Clinical Epidemiology, Aarhus University Hospital , Olof Palmes All\u00e9 43\u201345, 8200 Aarhus N ,","place":["Denmark"]},{"name":"Department of Clinical Medicine, Faculty of Health, Aarhus University , Palle Juul-Jensens Boulevard 82, 8200 Aarhus N ,","place":["Denmark"]},{"name":"Department of Cardiology, G\u00f8dstrup Regional Hospital , Herning ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,11,18]]},"reference":[{"key":"2025010309483153500_ehae736-B1","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/s41569-022-00787-6","article-title":"Epidemiology and prevention of venous thromboembolism","volume":"20","author":"Lutsey","year":"2023","journal-title":"Nat Rev Cardiol"},{"key":"2025010309483153500_ehae736-B2","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.ejvs.2014.05.001","article-title":"Editor\u2019s Choice\u2014efficacy and safety of the new oral anticoagulants dabigatran, rivaroxaban, apixaban, and edoxaban in the treatment and secondary prevention of venous thromboembolism: a systematic review and meta-analysis of phase III trials","volume":"48","author":"Kakkos","year":"2014","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"2025010309483153500_ehae736-B3","doi-asserted-by":"publisher","first-page":"4208","DOI":"10.1093\/eurheartj\/ehx003","article-title":"Diagnosis and management of acute deep vein thrombosis: a joint consensus document from the European Society of Cardiology working groups of aorta and peripheral vascular diseases and pulmonary circulation and right ventricular function","volume":"39","author":"Mazzolai","year":"2018","journal-title":"Eur Heart J"},{"key":"2025010309483153500_ehae736-B4","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1093\/eurheartj\/ehz405","article-title":"2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)","volume":"41","author":"Konstantinides","year":"2020","journal-title":"Eur Heart J"},{"key":"2025010309483153500_ehae736-B5","doi-asserted-by":"publisher","first-page":"e1001388","DOI":"10.1371\/journal.pmed.1001388","article-title":"Use of non-steroidal anti-inflammatory drugs that elevate cardiovascular risk: an examination of sales and essential medicines lists in low-, middle-, and high-income countries","volume":"10","author":"McGettigan","year":"2013","journal-title":"PLoS Med"},{"key":"2025010309483153500_ehae736-B6","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1093\/ehjcvp\/pvaa073","article-title":"Prescriber responsibility, predictors for initiation, and 20-year trends in use of non-aspirin non-steroidal anti-inflammatory drugs in patients with cardiovascular contraindications: a nationwide cohort study","volume":"7","author":"Schmidt","year":"2021","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2025010309483153500_ehae736-B7","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/s0140-6736(13)60900-9","article-title":"Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials","volume":"382","author":"Coxib and traditional NSAID Trialists' (CNT) Collaboration","year":"2013","journal-title":"Lancet"},{"key":"2025010309483153500_ehae736-B8","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1038\/s41569-020-0366-z","article-title":"Cardiovascular effects and safety of (non-aspirin) NSAIDs","volume":"17","author":"Schjerning","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"2025010309483153500_ehae736-B9","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1007\/s10147-019-01415-z","article-title":"Use of direct oral anti-coagulants for the treatment of venous thromboembolism in patients with advanced cancer: a prospective observational study","volume":"24","author":"Oyakawa","year":"2019","journal-title":"Int J Clin Oncol"},{"key":"2025010309483153500_ehae736-B10","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1001\/jamainternmed.2014.946","article-title":"Bleeding risk of patients with acute venous thromboembolism taking nonsteroidal anti-inflammatory drugs or aspirin","volume":"174","author":"Davidson","year":"2014","journal-title":"JAMA Intern Med"},{"key":"2025010309483153500_ehae736-B11","doi-asserted-by":"publisher","first-page":"563","DOI":"10.2147\/clep.S179083","article-title":"The Danish health care system and epidemiological research: from health care contacts to database records","volume":"11","author":"Schmidt","year":"2019","journal-title":"Clin Epidemiol"},{"key":"2025010309483153500_ehae736-B12","doi-asserted-by":"publisher","first-page":"569","DOI":"10.2147\/clep.S311450","article-title":"The validity of Danish prescription data to measure use of aspirin and other non-steroidal anti-inflammatory drugs and quantification of bias due to non-prescription drug use","volume":"13","author":"Gaster","year":"2021","journal-title":"Clin Epidemiol"},{"key":"2025010309483153500_ehae736-B13","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s10654-014-9930-3","article-title":"The danish civil registration system as a tool in epidemiology","volume":"29","author":"Schmidt","year":"2014","journal-title":"Eur J Epidemiol"},{"key":"2025010309483153500_ehae736-B14","doi-asserted-by":"publisher","first-page":"449","DOI":"10.2147\/clep.S91125","article-title":"The Danish National Patient Registry: a review of content, data quality, and research potential","volume":"7","author":"Schmidt","year":"2015","journal-title":"Clin Epidemiol"},{"key":"2025010309483153500_ehae736-B15","doi-asserted-by":"publisher","first-page":"e012832","DOI":"10.1136\/bmjopen-2016-012832","article-title":"Positive predictive value of cardiovascular diagnoses in the Danish National Patient Registry: a validation study","volume":"6","author":"Sundb\u00f8ll","year":"2016","journal-title":"BMJ Open"},{"key":"2025010309483153500_ehae736-B16","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1161\/circulationaha.114.009107","article-title":"30-year mortality after venous thromboembolism: a population-based cohort study","volume":"130","author":"S\u00f8gaard","year":"2014","journal-title":"Circulation"},{"key":"2025010309483153500_ehae736-B17","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1093\/ije\/dyw213","article-title":"Data resource profile: the Danish National Prescription Registry","volume":"46","author":"Potteg\u00e5rd","year":"2017","journal-title":"Int J Epidemiol"},{"key":"2025010309483153500_ehae736-B18","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1002\/pds.3881","article-title":"The potential drug-drug interaction between proton pump inhibitors and warfarin","volume":"24","author":"Henriksen","year":"2015","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2025010309483153500_ehae736-B19","doi-asserted-by":"publisher","first-page":"493","DOI":"10.2147\/clep.S400834","article-title":"Positive predictive value of non-traumatic bleeding diagnoses in the Danish National Patient Register","volume":"15","author":"Thaarup","year":"2023","journal-title":"Clin Epidemiol"},{"key":"2025010309483153500_ehae736-B20","doi-asserted-by":"publisher","first-page":"327","DOI":"10.2147\/clep.S37188","article-title":"Positive predictive value of the International Classification of Diseases, 10th edition diagnosis codes for anemia caused by bleeding in the Danish National Registry of Patients","volume":"4","author":"Zalfani","year":"2012","journal-title":"Clin Epidemiol"},{"key":"2025010309483153500_ehae736-B21","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.thromres.2022.02.013","article-title":"Validation of the Danish Comorbidity Index for Acute Myocardial Infarction for predicting one-year mortality in patients with venous thromboembolism","volume":"212","author":"Bonnesen","year":"2022","journal-title":"Thromb Res"},{"key":"2025010309483153500_ehae736-B22","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1093\/ije\/dyr213","article-title":"Competing risks in epidemiology: possibilities and pitfalls","volume":"41","author":"Andersen","year":"2012","journal-title":"Int J Epidemiol"},{"key":"2025010309483153500_ehae736-B23","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1001\/jama.2024.4970","article-title":"Accounting for competing risks in clinical research","volume":"331","author":"Austin","year":"2024","journal-title":"JAMA"},{"key":"2025010309483153500_ehae736-B24","doi-asserted-by":"publisher","first-page":"3484","DOI":"10.1182\/blood-2002-01-0108","article-title":"Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis","volume":"100","author":"Prandoni","year":"2002","journal-title":"Blood"},{"key":"2025010309483153500_ehae736-B25","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1111\/j.1538-7836.2006.02082.x","article-title":"Fatal pulmonary embolism and fatal bleeding in cancer patients with venous thromboembolism: findings from the RIETE registry","volume":"4","author":"Monreal","year":"2006","journal-title":"J Thromb Haemost"},{"key":"2025010309483153500_ehae736-B26","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s11239-020-02180-x","article-title":"Cancer associated thrombosis in everyday practice: perspectives from GARFIELD-VTE","volume":"50","author":"Weitz","year":"2020","journal-title":"J Thromb Thrombolysis"},{"key":"2025010309483153500_ehae736-B27","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/nrrheum.2015.30","article-title":"Active-comparator design and new-user design in observational studies","volume":"11","author":"Yoshida","year":"2015","journal-title":"Nat Rev Rheumatol"},{"key":"2025010309483153500_ehae736-B28","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.jclinepi.2009.07.001","article-title":"Construction of drug treatment episodes from drug-dispensing histories is influenced by the gap length","volume":"63","author":"Gardarsdottir","year":"2010","journal-title":"J Clin Epidemiol"},{"key":"2025010309483153500_ehae736-B29","doi-asserted-by":"publisher","first-page":"k3426","DOI":"10.1136\/bmj.k3426","article-title":"Diclofenac use and cardiovascular risks: series of nationwide cohort studies","volume":"362","author":"Schmidt","year":"2018","journal-title":"BMJ"},{"key":"2025010309483153500_ehae736-B30","doi-asserted-by":"publisher","first-page":"20","DOI":"10.7326\/m21-0717","article-title":"Risk for recurrent venous thromboembolism and bleeding with apixaban compared with rivaroxaban: an analysis of real-world data","volume":"175","author":"Dawwas","year":"2022","journal-title":"Ann Intern Med"},{"key":"2025010309483153500_ehae736-B31","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1093\/aje\/kwg231","article-title":"Evaluating medication effects outside of clinical trials: new-user designs","volume":"158","author":"Ray","year":"2003","journal-title":"Am J Epidemiol"},{"key":"2025010309483153500_ehae736-B32","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1093\/eurheartj\/eht042","article-title":"Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy","volume":"34","author":"Agewall","year":"2013","journal-title":"Eur Heart J"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/46\/1\/58\/60677368\/ehae736.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/46\/1\/58\/60677368\/ehae736.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T09:49:06Z","timestamp":1735897746000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/46\/1\/58\/7900494"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,18]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,11,18]]},"published-print":{"date-parts":[[2025,1,3]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehae736","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,1,1]]},"published":{"date-parts":[[2024,11,18]]}}}